| Biomarker ID | 457 |
| PMID | 19773444 |
| Year | 2009 |
| Biomarker | MIC-1 (Macrophage inhibitory cytokine 1) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Blood |
| Subjects | Humans |
| Regulation | Downregulated after one round of chemotherapy |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-TAp63 pathway, p73 transcription factor network,p53 signaling pathway,BDNF signaling pathway |
| Experiment | Overall survival Vs No survival in patients Post One round of Docetaxel chemotherapy |
| Type of Biomarker | Predictive |
| Cohort | Plasma/serum samples were collected from a cohort of 43 men with metastatic HRPC (Hormone Refactory Prostate Cancer) treated with chemotherapy |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.002 |
| Method Used | ELISA |
| Clinical | Yes |
| Remarks | Serum/Plasma concentration was used to evaluate status of the biomarker. Overall survival was defined as the time from commencement of chemotherapy to the time of death or last follow-up |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | GDF15 |